Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer

Cancer Research

Volumn 72, Issue 1, 2012, Pages 220-229

  McCartan, Damian ^a   Bolger, Jarlath C ^a   Fagan, Aiĺis ^b   Byrne, Christopher ^a   Hao, Yuan ^b   Qin, Li ^c   McIlroy, Marie ^a   Xu, Jianming ^c   Hill, Arnold D ^a   Ó Gaora, Peadar ^b   Young, Leonie S ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; PLACEBO; PROTEIN ADAM22; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CANCER TISSUE; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ADAM PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NERVE TISSUE PROTEINS; NUCLEAR RECEPTOR COACTIVATOR 1; RECEPTORS, ESTROGEN; TRANSCRIPTOME;

EID: 84855364818     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1976     Document Type: Article

References (33)

1. Bentires-Alj M, Clarke RB, Jonkers J, Smalley M, Stein T. It's all in the details: methods in breast development and cancer. Breast Cancer Res 2009;11:305.
2. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, et al. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-62.
3. McIlroy M, McCartan D, Early S,OGaora P, Pennington S, Hill AD, et al. Interaction of developmental transcription factor HOXC11 with steroid receptor coactivator SRC-1 mediates resistance to endocrine therapy in breast cancer. Cancer Res 2010;70:1585-94.
4. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, et al. Coassociation of ER and p160 proteins predicts resistance to endocrine treatment; SRC-1 is an independent predictor of breast cancer recurrence. Clin Cancer Res 2009;15:2098-106.
5. Goel A, Janknecht R. Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 2004;279:14909-16. (Pubitemid 38618881)
6. Qin L, Chen X, Wu Y, Feng Z, He T, Wang L, et al. Steroid receptor coactivator-1 upregulates integrin alpha;5 expression to promote breast cancer cell adhesion and migration. Cancer Res 2011;71:1742-51.
7. Qin L, Liu Z, Chen H, Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 2009;69:3819-27.
8. Myers E, Hill AD, Kelly G, McDermott EW, O'Higgins NJ, Buggy Y, et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005;11:2111-22. (Pubitemid 40490167)
9. Al-azawi D, Ilroy MM, Kelly G, Redmond AM, Bane FT, Cocchiglia S, et al. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008;27:3021-31. (Pubitemid 351668011)
10. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985;117:1409-17 (Pubitemid 15238118)
11. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
12. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008;9:R137.
13. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
14. Wu Z, Irizarry RA. Preprocessing of oligonucleotide array data. Nat Biotech 2004;22:656-7.
15. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27 (Pubitemid 44906106)
16. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289.
18. Dillon MF, Stafford AT, Kelly G, Redmond AM, McIlroy M, Crotty TB, et al. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer 2008;15:745-53
19. Lanz RB, Bulynko Y, Malovannaya A, Labhart P, Wang L, Li W, et al. Global characterization of transcriptional impact of the SRC-3 coregulator. Mol Endocrinol 2010;24:859-72.
20. Smeenk L, van Heeringen SJ, Koeppel M, van Driel MA, Bartels SJ, Akkers RC, et al. Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res 2008;36:3639-54. (Pubitemid 351917528)
21. Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009;15:1140-4.
22. Zhu P, Sang Y, Xu H, Zhao J, Xu R, Sun Y, et al. ADAM22 plays an important role in cell adhesion and spreading with the assistance of 14- 3-3. Biochem Biophys Res Commun 2005;331:938-46. (Pubitemid 40692451)
23. Sagane K, Sugimoto H, Akaike A. Biological characterisation of ADAM22 variants reveals the importance of a disintegrin domain sequence in cell surface expression. J Recept Signal Transduct Res 2010;30:72-7.
24. Fukata Y, Adesnik H, Iwanaga T, Bredt DS, Nicoll RA. and Fukata, M Epilepsy-related ligand receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006;313:1792-5. (Pubitemid 44454156)
25. Voight BF, Kudaravalli S, Wen X, Pritchard JK. A map of recent positive selection in the human genome. PLoS Biol 2006;4:e72.
26. Sagane K, Sugimoto H, Akaike A. Metalloproteinase-like, disintegrin- like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain. Biochem J 1998;334:93-8. (Pubitemid 28420976)
27. Novak U. ADAM proteins in the brain. J Clin Neurosci 2004;11:227-35. (Pubitemid 38315974)
28. Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, O'Malley BW, et al. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis. Proc Natl Acad Sci U S A 2009;106:151-6.
29. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev 2008;8:523-34 (Pubitemid 351881853)
30. Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK. LGI1, a putative tumour metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinase in glioma cells through the ERK1/2 pathway. J Biol Chem 2004;279:23151-7. (Pubitemid 38685620)
31. Gabellini N, Masola V. Expression of LGI1 impairs proliferation and survival of HeLa cells. Int J Cell Biol 2009;2009:417197.
32. Gabellini N, Masola V, Quartesan S, Oselladore B, Nobile C, Michelucci R, et al. Increased expression of LGI1 gene triggers growth inhibition and apoptosis of neuroblastoma cells. J Cell Physiol 2006;207:711-21. (Pubitemid 43668235)
33. York B, O'Malley BW. Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem 2010;285:38743-50.